Its important to consider not only the primary health objectivebe it diabetes control or weight managementbut also potential side effects, how the medication fits into ones overall lifestyle and any underlying health conditions
For semaglutide , a phase 2 trial published in the New England Journal of Medicine (2021) examined daily semaglutide 0.4 mg in NASH patients and found that 59% achieved NASH resolution compared to 17% with placebo
It helps eliminate toxins and ingest chemicals that the body has already absorbed and also helps intercept and neutralize toxins in the digestive system before the body has a chance to absorb them
Glucagon-like peptide-1 (GLP-1), which is secreted from gut cells and hindbrain areas, has been studied in metabolic diseases such as obesity and diabetes, and was shown to control glucose metabolism and insulin resistance
The supplement may provide incremental benefits for some users, but it is unlikely to be the transformative solution that the marketing materials imply
GLP-1s can go a long way when combined with a healthy diet and regular exercise